Clinical trials: Embryonal Tumor
Brain Tumor, Glioblastoma
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma.
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Trial name
- NCT01434602
- Testing
- everolimus, sorafenib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Genetic Testing, Breast Cancer
Video Education With Result Dependent dIsclosure
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic…
- Conditions
- Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- VERDI (NCT05225428)
- Testing
- Video Education, Genetic Counseling
- Where
- United States
- Volunteers
- 1,334 people
- Sponsor
- Dana-Farber Cancer Institute
Hydatidiform Mole
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
This observational study aims to establish a national cohort of patients with hydatidiform mole (molar pregnancy) to investigate its malignant transformation rate and malignant transformation mechanisms, with the goal of…
- Trial name
- CN-HM-01 (NCT07202728)
- Testing
- No intervention
- Where
- 14 sites in China
- Volunteers
- 1,489 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Head and Neck Cancer
Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and saliva from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898300
- Testing
- biologic sample preservation procedure, biopsy
- Where
- 98 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Radiation Therapy Oncology Group
Metastatic Melanoma
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
This is an open bi-centric prospective non-randomized study in patients with metastatic melanoma treated with a first line treatment of Nivolumab +/- Ipilimumab.
- Trial name
- IMMUNONIVO (NCT03225365)
- Testing
- Blood and biopsy sampling
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon
Glioblastoma
Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide.
- Trial name
- NCT01907165
- Testing
- Temozolomide, Disulfiram, Copper gluconate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Glioblastoma
Phase I Trial of pH Resections of GBM at VA
Glioblastoma is an infiltrating tumor that is difficult to visualize in surgery and on standard images. A special pH (acid-base) related magnetic resonance imaging (MRI) has been developed to better see infiltrating tumor.
- Trial name
- NCT07218367
- Testing
- pH MRI based resection of GBM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Exudative Retinal Detachment, Uveal Melanoma
TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy
Proton beam therapy is a safe irradiation modality for choroidal melanoma. But often after irradiation the exudation increases resulting in an exudative retinal detachment requiring vitreoretinal surgery.
- Trial name
- NCT02379000
- Testing
- Triamcinolone Acetonide, Transpupillary thermotherapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Recurrent Glioblastoma
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
This is an open-label, multicenter, phase II study to evaluate the safety, efficacy, and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with recurrent glioblastoma.
- Trial name
- NCT06598787
- Testing
- BL-B01D1 for Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Melanoma
The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure
1.1 To detect reproducible variations of serum 25-hydroxyvitamin D levels throughout the course of one year in relationship to objectively measured levels of ultraviolet exposure.
- Trial name
- NCT00832533
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance
Liver Metastases, Lung Metastases
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase II trial studies the effectiveness of the combination of stereotactic radiation therapy and ipilimumab in patients with metastatic melanoma that has spread to four or fewer sites in the body (oligometastatic).
- Conditions
- Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma
- Trial name
- NCT02107755
- Testing
- ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00006263
- Testing
- filgrastim, carboplatin, temozolomide
- Where
- United States
- Sponsor
- NYU Langone Health
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
Stage IV Melanoma, Recurrent Melanoma
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00019448
- Testing
- gp100 antigen, interleukin-2
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients
Primary Objective: 1. To determine whether the use of a fibrin sealant applied to superficial groin soft tissues following node dissection can result in decreased cumulative postoperative drainage, earlier drain removal, and…
- Trial name
- NCT00506311
- Testing
- Fibrin Sealant
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens
Eligible adult patients with new diagnosis of gliobastoma are enrolled to receive 3 weekly vaccinations of the study drug PEP-CMV 1-3 days following standard of care chemoradiation.
- Trial name
- PERFORMANCE (NCT01854099)
- Testing
- PEP-CMV
- Sponsor
- University of Florida
Neuroendocrine Tumor, Liver Metastases
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options.
- Conditions
- Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour
- Trial name
- LUTARTERIAL (NCT04837885)
- Testing
- Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection
- Where
- 4 sites in France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Bordeaux
Head and Neck Neoplasms, MSI-H Cancer
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or…
- Conditions
- Head and Neck Neoplasms, MSI-H Cancer, Melanoma
- Trial name
- TIRACAN (NCT05483400)
- Testing
- Tiragolumab and atezolizumab
- Where
- Netherlands
- Volunteers
- 97 people
- Sponsor
- University Medical Center Groningen
Glioblastoma
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
This research study is studying a chemotherapy as a possible treatment for recurrent glioblastoma that has not responded to bevacizumab. The name of the study drug involved in this study is Ponatinib.
- Trial name
- NCT02478164
- Testing
- Ponatinib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.